Repositrak, Inc. (NYSE:TRAK – Get Free Report)’s share price was down 4.3% during trading on Wednesday following insider selling activity. The company traded as low as $20.38 and last traded at $20.60. Approximately 45,903 shares were traded during trading, a decline of 3% from the average daily volume of 47,117 shares. The stock had previously closed at $21.53.
Specifically, CEO Randall K. Fields sold 2,500 shares of the firm’s stock in a transaction on Wednesday, June 11th. The stock was sold at an average price of $21.00, for a total value of $52,500.00. Following the sale, the chief executive officer now owns 177,000 shares of the company’s stock, valued at approximately $3,717,000. This trade represents a 1.39% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Randall K. Fields sold 3,500 shares of the firm’s stock in a transaction on Tuesday, June 10th. The shares were sold at an average price of $21.52, for a total value of $75,320.00. Following the sale, the chief executive officer now directly owns 179,500 shares in the company, valued at approximately $3,862,840. This trade represents a 1.91% decrease in their position. The disclosure for this sale can be found here. In other news, CEO Randall K. Fields sold 1,500 shares of Repositrak stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $21.74, for a total value of $32,610.00. Following the completion of the transaction, the chief executive officer now directly owns 183,000 shares of the company’s stock, valued at approximately $3,978,420. This trade represents a 0.81% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.
Analyst Ratings Changes
Separately, Wall Street Zen upgraded Repositrak from a “hold” rating to a “buy” rating in a research note on Thursday, May 22nd.
Repositrak Trading Up 1.5%
The company has a market cap of $382.15 million, a price-to-earnings ratio of 61.50 and a beta of 0.54.
Repositrak Increases Dividend
The company also recently declared a quarterly dividend, which will be paid on Friday, November 14th. Investors of record on Tuesday, September 30th will be given a dividend of $0.02 per share. The ex-dividend date is Tuesday, September 30th. This represents a $0.08 annualized dividend and a dividend yield of 0.38%. This is an increase from Repositrak’s previous quarterly dividend of $0.02. Repositrak’s dividend payout ratio (DPR) is 23.53%.
Institutional Investors Weigh In On Repositrak
A hedge fund recently raised its stake in Repositrak stock. Ellsworth Advisors LLC raised its holdings in shares of Repositrak, Inc. (NYSE:TRAK – Free Report) by 10.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 31,289 shares of the company’s stock after acquiring an additional 2,997 shares during the quarter. Ellsworth Advisors LLC owned approximately 0.17% of Repositrak worth $634,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 27.35% of the company’s stock.
Repositrak Company Profile
Park City Group, Inc, a software-as-a-service provider, designs, develops, and markets proprietary software products in North America. The company offers ReposiTrak MarketPlace, a supplier discovery and B2B e-commerce solution; ReposiTrak Compliance and Food Safety solutions, which reduces potential regulatory and legal risk from their supply chain partners; and ReposiTrak Supply Chain solutions that enables customers to manage relationships with suppliers.
Further Reading
- Five stocks we like better than Repositrak
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Ignore the Noise—Samsara Stock Is Still a Strong Buy
- What is the Dogs of the Dow Strategy? Overview and Examples
- 3 Stocks Set to Double—And There’s Still Time to Buy
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Analysts Can’t Get Enough of These Little-Known Biopharma Stocks
Receive News & Ratings for Repositrak Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repositrak and related companies with MarketBeat.com's FREE daily email newsletter.